AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X

Find the latest Drugs in Development and Pipeline Prospector News of Curia.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Curia
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
26 Corporate Circle, Albany, New York 12203
Telephone
Telephone
+1 518.512.2000

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

left grey arrow
right gray arrow

Details:

RBI-4000, is a self-replicating (srRNA) rabies vaccine, which is investigated in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.


Lead Product(s): RBI-4000

Therapeutic Area: Infections and Infectious Diseases Product Name: RBI-4000

Highest Development Status: Phase IProduct Type: Vaccine

Recipient: Replicate Bioscience

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 13, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and to generate high affinity antibodies that recognize different epitopes on the SARS-CoV-2 spike protein.


Lead Product(s): Murine Monoclonal Antibody

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 12, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.


Lead Product(s): Cannabidiol,Isoflurane

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: IHL-216A

Highest Development Status: PreclinicalProduct Type: Small molecule

Recipient: Incannex Healthcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.


Lead Product(s): Liafensine

Therapeutic Area: Psychiatry/Psychology Product Name: DB104

Highest Development Status: Phase IIProduct Type: Small molecule

Recipient: Denovo Biopharma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 28, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

As part of the collaboration, Curia’s experienced process development team will support the GMP production of Replicate Bioscience’s srRNA vectors up to eight-liter scale (8L), which can be used in Phase 1 through pivotal clinical trials.


Lead Product(s): srRNA Therapeutic

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Replicate Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 09, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.


Lead Product(s): Clascoterone

Therapeutic Area: Dermatology Product Name: Winlevi

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Cassiopea

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 30, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.


Lead Product(s): Bryostatin-1

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Recipient: BryoLogyx Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 13, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Curia has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at Curia’s drug product manufacturing facility in Albuquerque, New Mexico.


Lead Product(s): ChAdOx1 nCoV-19

Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

Highest Development Status: Phase IIIProduct Type: Vaccine

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 03, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Curia will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.


Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Tryp Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 13, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The companies together are undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.


Lead Product(s): Merimepodib,Remdesivir

Therapeutic Area: Infections and Infectious Diseases Product Name: VX-497

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: BioSig Technologies

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 08, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY